+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

France Dry Powdered Inhaler Market 2019-2025

  • ID: 4987998
  • Report
  • January 2020
  • Region: France
  • Orion Market Research Private Limited

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
France Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

France dry powdered inhaler market is anticipated to grow at a substantial rate of around 3.5% during the forecast period. Well-developed healthcare infrastructure and medical device industry coupled with the significant prevalence of asthma and COPD in the country are influencing factors for the market growth. As per French government agency, Business France, the country ranked as 4th globally and second in Europe for medical device and technology industry. There are about 1,300 to 1,350 companies in French device manufacturer that generated a revenue of around $32 billion in 2017. The country is generating about $9.5 billion in 2017 by export of medical devices. The medical device market is providing employment to about 85,000 people in the country. This provides a significant base for the growth of medical Dry Powdered Inhaler market over the forecast period.

France dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhaler to cater to a wide range of customers within the country and across the globe. The major players of the France dry powdered inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Air Liquide S.A. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Major Dry Powdered Inhaler manufacturing company in France is Air Liquide. In April 2018, the company acquired a French start-up company EOVE for the extension of service offering of home healthcare activities. In September2017 Air Liquide acquired Sogo Sangyo Kabushiki Kaisha for expanding its healthcare business in Japan. In September2017 company has launched its first e-health solution Chronic care Connect which is a remote monitoring solution. In January 2017 Air Liquide acquired Oxymaster for expanding its healthcare business in South America.

Research Methodology

The market study of the France dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for dry powdered inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. France Dry Powdered Inhaler Market Research and Analysis by Type
2. France Dry Powdered Inhaler Market Research and Analysis by Application
3. France Dry Powdered Inhaler Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the France dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the France Dry Powdered Inhaler market.
  • Insights about market determinants which are stimulating the France dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. France Dry Powdered Inhaler Market by Type
5.1.1. Preventive Inhaler
5.1.2. Reliever Inhaler
5.1.3. Long Acting Bronchodilators Inhaler
5.2. France Dry Powdered Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. France Dry Powdered Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Company Profiles
6.1. 3M Co.
6.2. Acorda Therapeutics, Inc.
6.3. Adamis Pharmaceuticals Corp.
6.4. Adherium Ltd.
6.5. Air Liquide S.A.
6.6. AstraZeneca PLC
6.7. Bespak
6.8. Boehringer Ingelheim International GmbH
6.9. Chiesi Farmaceutici S.P.A.
6.10. GlaxoSmithKline PLC
6.11. H&T Presspart Manufacturing Ltd.
6.12. Koninklijke Philips N.V.
6.13. Novartis AG
6.14. Omron Healthcare Inc.
6.15. ResMed Corp.
6.16. Pulmatrix Inc.
6.17. Savara, Inc.
6.18. Teicos Pharma Ltd.
6.19. Teva Pharmaceuticals Industries Ltd.
6.20. Vitalograph Ltd.
Note: Product cover images may vary from those shown
  • 3M Co.
  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corp.
  • Adherium Ltd.
  • Air Liquide S.A.
  • AstraZeneca PLC
  • Bespak
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici S.P.A.
  • GlaxoSmithKline PLC
  • H&T Presspart Manufacturing Ltd.
  • Koninklijke Philips N.V.
  • Novartis AG
  • Omron Healthcare Inc.
  • ResMed Corp.
  • Pulmatrix Inc.
  • Savara, Inc.
  • Teicos Pharma Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Vitalograph Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll